Aventis Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc., No. 11-1335 (Fed. Cir. May 20, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Aventis Pharmaceuticals, Inc. and Albany Molec ular Research, Inc. (AMRI) (collectively “Appellants”) appeal a stipulated judgment of non infringement entered by the U.S. District Court for the District of New Jersey. The parties stipulated to non infringement following the di s- trict court’s Markman opinion of January 13, 2011, which consolidated numerous patent infringement cases and construed terms of AMRI’s U.S. Patent No.